Publication at First Faculty of Medicine, Second Faculty of Medicine |
2022
Abstract
Here, we report seven adult STAT1 GOF patients (two with novel mutations) with an uneventful course of COVID-19 vaccination, and/or SARS-CoV-2 infection, including two patients receiving JAK inhibitor ruxolitinib.